GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4Results posted

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical Study

Lead sponsor

Novo Nordisk A/S

Assets

Liraglutide / Semaglutide

Listed sites

Recruiting sites

—

Enrollment

500

actual

Study population

Obesity / overweight

Key I/E criterion

—

Primary endpoint

•≥10% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05579249

Org study IDNN9536-4741

Secondary IDU1111-1263-7301World Health Organization (WHO)

Timeline

Milestones

Study first posted2022-10-13actual

Study start2023-01-19actual

Primary completion2024-11-27actual

Study completion2024-11-27actual

Last update posted2026-01-14actual

Results first posted2026-01-14actual

Assets

Investigational agents

Liraglutide Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Body mass index (BMI) greater than equal to 30.0 kilogram per meter square (kg/m^2).

•Employed at randomisation by one of the selected employers and expecting to be so for the duration of the study.

Exclusion criteria

•Known or suspected hypersensitivity or contraindications to Wegovy or related products according to the label.

•Known or suspected hypersensitivity or contraindications to all of the other Anti-Obesity Medications (AOMs) for chronic weight management (Xenical, Qsymia, Contrave, and Saxenda) or related products according to the labels.

•Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.

•History of type 1 or type 2 diabetes mellitus.

•Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion might jeopardise participant's safety or compliance with protocol.

Endpoints (18)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Patient-reported / QoL

Safety / tolerability / PK

Other (unclassified)

Weight & body composition

8 endpoints

Primary/registry result

Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

Time frame:At end of treatment (week 52)

≥10% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mgYes	132	—
No	75	—
Other Anti-obesity Medications (AOMs)Yes	61	—
No	116	—

Odds Ratio (OR)3.1895% CI2.12 – 4.78p<0.0001Regression, Linear

Week 52 responses were analysed using a binary regression model with randomized treatment as factor and baseline body weight as covariate.

Primary/protocol endpoint

Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

Time frame:At end of treatment (week 52)

≥10% weight-loss responders

threshold achievement, improvement

Secondary/registry result

Percentage Change in Body Weight

Time frame:Baseline (week 0), end of treatment (week 52)

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (mean), Percentange change in body weight	95% CI
Semaglutide 2.4 mg	-13.6	—
Other Anti-obesity Medications (AOMs)	-7.4	—

Secondary/registry result

Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no)

Time frame:At end of treatment (week 52)

≥15% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mgYes	93	—
No	114	—
Other Anti-obesity Medications (AOMs)Yes	25	—
No	152	—

Secondary/registry result

Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no)

Time frame:At end of treatment (week 52)

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mgYes	49	—
No	158	—
Other Anti-obesity Medications (AOMs)Yes	8	—
No	169	—

Secondary/protocol endpoint

Percentage Change in Body Weight

Time frame:Baseline (week 0), end of treatment (week 52)

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Number of Participants Who Achieved Greater Than or Equal to (≥) 15.0% Body Weight Reduction (Yes/no)

Time frame:At end of treatment (week 52)

≥15% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Number of Participants Who Achieved Greater Than or Equal to (≥) 20.0% Body Weight Reduction (Yes/no)

Time frame:At end of treatment (week 52)

≥20% weight-loss responders

threshold achievement, improvement

Patient-reported / QoL

6 endpoints

Secondary/registry result

Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain

Time frame:Baseline (week 0), end of treatment (week 52)

IWQOL-Lite physical

change from baseline, improvement

Posted result

Group	Value (mean), Score on a scale	95% CI
Semaglutide 2.4 mg	25.6	—
Other Anti-obesity Medications (AOMs)	22.6	—

Secondary/registry result

Number of Participants Who Achieved Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain Score Greater Than or Equal to (≥) 14.6 (Yes/no)

Time frame:At end of treatment (week 52)

IWQOL-Lite physical

threshold achievement, improvement

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mgYes	138	—
No	51	—
Other Anti-obesity Medications (AOMs)Yes	108	—
No	55	—

Secondary/registry result

Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)

Time frame:Baseline (week 0), end of treatment (week 52)

change from baseline, improvement

Posted result

Group	Value (mean), Score on a scale	95% CI
Semaglutide 2.4 mg	-0.034	—
Other Anti-obesity Medications (AOMs)	-0.016	—

Secondary/protocol endpoint

Change in Impact of Weight on Quality of Life-Lite-Clinical Trials Version (IWQOL-Lite-CT) Physical Function Domain

Time frame:Baseline (week 0), end of treatment (week 52)

IWQOL-Lite physical

change from baseline, improvement

Secondary/protocol endpoint

Time frame:At end of treatment (week 52)

IWQOL-Lite physical

threshold achievement, improvement

Secondary/protocol endpoint

Change in Work Limitations Questionnaire 25-item Version (WLQ-25), Total Score (TS)

Time frame:Baseline (week 0), end of treatment (week 52)

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Secondary/registry result

Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no)

Time frame:At end of treatment (week 52)

threshold achievement, descriptive

Posted result

Group	Value (count_of_participants), Participants	95% CI
Semaglutide 2.4 mgYes	168	—
No	82	—
Other Anti-obesity Medications (AOMs)Yes	113	—
No	137	—

Secondary/protocol endpoint

Number of Participants Covered by Study Product Greater Than or Equal to (≥) 80% of Days (Yes/no)

Time frame:At end of treatment (week 52)

threshold achievement, descriptive

Other (unclassified)

2 endpoints

Secondary/registry result/low confidence

Percentage of Days Covered (PDC) by Study Product

Time frame:From week 0 to week 52

descriptive

Posted result

Group	Value (mean), Percentage of days covered	95% CI
Semaglutide 2.4 mg	83.7	—
Other Anti-obesity Medications (AOMs)	70.8	—

Secondary/protocol endpoint/low confidence

Percentage of Days Covered (PDC) by Study Product

Time frame:From week 0 to week 52

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.